How we approach patient evaluation for hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1259-1268

  Hamadani, M ^a   Craig, M ^a   Awan, F T ^b   Devine, S M ^c  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

hematopoietic stem cell transplant; patient evaluation; patient selection; workup

Indexed keywords

MELPHALAN;

ACCESS TO INFORMATION; CLINICAL EVALUATION; COMORBIDITY; CONSULTATION; CYTOMEGALOVIRUS INFECTION; DENTAL CARE; DRUG DOSE REDUCTION; DRUG MEGADOSE; HEALTH STATUS; HEART FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KARNOFSKY PERFORMANCE STATUS; KIDNEY FUNCTION; LIVER FUNCTION; LUNG FUNCTION; NUTRITIONAL ASSESSMENT; PATIENT ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REVIEW; SAFETY; VIRUS DETECTION; WEB BROWSER;

EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC;

EID: 77955583042     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.94     Document Type: Review

References (76)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Blume KG, Amylon MD. The evaluation and counseling of candidates for hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hemato- poietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 449-462.
3. www.medicalcenter.osu.edu/patientcare/healthcare-services/blood- disorders/bone-marrow-transplantation/Pages/index.aspx.
4. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735-740.
5. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763.
6. Ganti AK, Lee SJ, Vose JM, Devetten MP, Bociek RG, Armitage JO et al. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. J Clin Oncol 2007; 25: 5643-5648.
7. Chatterjee R, Kottaridis PD. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies. Bone Marrow Transplant 2002; 30: 629-635.
8. Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the bone marrow transplant survivor study. Bone Marrow Transplant 2006; 37: 1023-1029.
9. Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 2007; 25: 3511-3517.
10. Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 2005; 20: 3539-3546.
11. Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L et al. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003; 32: 433-436.
12. Sloan JM, Ballen K. SCT in Jehovah's Witnesses: the bloodless transplant. Bone Marrow Transplant 2008; 41: 837-844.
13. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced- intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323.
14. Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006; 12: 61-67.
15. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non- Hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547-553.
16. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
17. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
18. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157-1163.
19. Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008; 26: 2162-2170.
20. Lee SJ, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285: 1034-1038.
21. Cahn JY, Labopin M, Schattenberg A, Reiffers J, Willemze R, Zittoun R et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1997; 11: 416-419.
22. Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996; 17: 993-1001.
23. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57-60.
24. Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, Dipersio JF et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 840-846.
25. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004; 25: 189-201.
26. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749-759.
27. Cooke KR, Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus- host disease? Bone Marrow Transplant 2004; 34: 753-765.
28. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257-1264.
29. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261-1269.
30. Singh AK, Karimpour SE, Savani BN, Guion P, Hope AJ, Mansueti JR et al. Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. Int J Radiat Oncol Biol Phys 2006; 66: 520-527.
31. Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C et al. Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 223-230.
32. Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A et al. The effect of smoking on allogeneic transplant outcomes. Biol Blood Marrow Transplant 2009; 15: 1277-1287.
33. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001; 28: 283-287.
34. Fujimaki K, Maruta A, Yoshida M, Sakai R, Tanabe J, Koharazawa H et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307-310.
35. Zangari M, Henzlova MJ, Ahmad S, Scigliano E, Isola L, Platnik J et al. Predictive value of left ventricular ejection fraction in stem cell transplantation. Bone Marrow Transplant 1999; 23: 917-920.
36. Bearman SI, Petersen FB, Schor RA, Denney JD, Fisher LD, Appelbaum FR et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
37. Jain B, Floreani AA, Anderson JR, Vose JM, Robbins RA, Rennard SI et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996; 17: 561-568.
38. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 2009; 15: 1265-1270.
39. Nakamae H, Hino M, Akahori M, Terada Y, Yamane T, Ohta K et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004; 76: 1-7.
40. Akahori M, Nakamae H, Hino M, Yamane T, Hayashi T, Ohta K et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant 2003; 31: 585-590.
41. Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant 2004; 34: 615-619.
42. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
43. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997-1003.
44. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
45. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310-316.
46. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant 2008; 14: 1239-1244.
47. Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant 2009; 44: 767-768.
48. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 541-551.
49. Kersting S, Hene RJ, Koomans HA, Verdonck LF. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1169-1175.
50. Kersting S, Dorp SV, Theobald M, Verdonck LF. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008; 14: 125-131. (Pubitemid 350286747)
51. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR et al. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32: 405-410.
52. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829. (Pubitemid 32953738)
53. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1094-1099.
54. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823-828.
55. Hamaguchi M, Yamada H, Gondo H, Takemoto Y, Mor- ishima Y, Kodera Y. Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan. Int J Hematol 2002; 75: 324-331.
56. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-1059.
57. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153.
58. Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249-257.
59. Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 2192-2198.
60. Krishnan A, Molina A, Zaia J, Nademanee A, Kogut N, Rosenthal J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857-3859.
61. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 1306-1313.
62. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59-66.
63. Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 864-871.
64. Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood 2009; 114: 2564-2566.
65. Woolfrey AE, Malhotra U, Harrington RD, McNevin J, Manley TJ, Riddell SR et al. Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood 2008; 112: 3484-3487.
66. IDSA Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Available from: . (Accessed on 21 February 2010).
67. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.
68. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hemato- poietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
69. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
70. Akintoye SO, Brennan MT, Graber CJ, McKinney BE, Rams TE, Barrett AJ et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicemia in hematopoietic stem cell and bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 581-588.
71. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
72. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 2008; 19: 1166-1171.
73. Andorsky DJ, Loberiza FR, Lee SJ. Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation. Bone Marrow Transplant 2006; 37: 889-895.
74. Heinonen H, Volin L, Zevon MA, Uutela A, Barrick C, Ruutu T. Stress among allogeneic bone marrow transplantation patients. Patient Educ Couns 2005; 56: 62-71.
75. Molassiotis A, van den Akker OB, Boughton BJ. Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors. Soc Sci Med 1997; 44: 317-325.
76. Meehan KR, Fitzmaurice T, Root L, Kimtis E, Patchett L, Hill J. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol 2006; 4: 187-190.